Clinical Trial Update: Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating talazoparib in HRR gene mutation-positive recurrent stage IV squamous cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Carcinoma

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: ATM Gene Mutation, ATR Gene Mutation | Phase 2 | Status: COMPLETED | Results posted: 2021-06-23